Back

Early SGLT2i therapy in patients with T2DM and ACS results in reduction in cardiovascular and renal outcomes- a propensity score matched multi-model retrospective registry analysis

30 August 2025 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Muhammad Usman Shah

Hull University Teaching Hospitals NHS Trust, Hull (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Association between the oxidative balance score and mortality in patients with metabolic syndrome
Professor J. Gao (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Dietary inflammatory index in progression and mortality risk of cardiovascular-kidney-metabolic syndrome: NHANES 1999-2018
Doctor Y. Wang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
The impact of microalbuminuria and proteinuria on cardiovascular outcomes in individuals with type 2 diabetes mellitus: a population-based, electronic health records study
Doctor M. Mohamed (London, GB)
Abstract Slides Video
Presentation thumbnail
Lower glomerular filtration rate is correlated with higher left heart remodeling in individuals with type 2 diabetes
Doctor N. Espinola-Zavaleta (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Associations of epicardial fat and markers of subclinical diastolic dysfunction in metabolic syndrome
Mrs B. Gustafsson (Turku, FI)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes and the heart (1)

The Event

Event poster

ESC Congress 2025

30 August 2025 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Beyond heart failure: impact of sodium-glucose co-transporter-2 inhibitors after acute coronary syndrome
thumbnail
Congress Presentation
SGLT2-'eyes' on the reno-protection prize: reduction of post-PCI contrast-associated AKI in diabetic patients using SGLT2 inhibitors
thumbnail
Congress Presentation
Glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors combination therapy after acute myocardial infarction in patients with type 2 diabetes mellitus: a dynamic duo

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources